Navigation Links
Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Abbott's Bioabsorbable Stent Technology Holds Promise as Future-Generation Treatment Option for Physicians Treating Patients with Coronary Artery Disease

ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Abbott today announced positive results from ABSORB, the world's first clinical trial evaluating the overall safety and performance of a fully bioabsorbable drug- eluting stent platform for the treatment of coronary artery disease. Six- month results from the first 30 patients in the trial, presented at the 56th Annual of Cardiology Scientific Session in New Orleans, demonstrated no stent thrombosis and a low (3.3 percent) hierarchical rate of ischemia-driven Major Adverse Cardiac Events (MACE), such as heart attack or repeat intervention.

"The encouraging results from the first 30 patients of ABSORB suggest that drug-eluting bioabsorbable stent technologies may be a promising future therapy option for physicians treating patients with heart disease," said Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, who is co-principal investigator of the study. "A drug eluting stent that would eventually disappear after restoring blood flow is an exciting concept that we look forward to further exploring."

The single MACE event reported was a non-Q-wave myocardial infarction. The same patient underwent a repeat intervention that occurred at the site of the original procedure, resulting in an overall target lesion revascularization rate of 3.3 percent. The trial results confirmed that the treatment effect of everolimus in the bioabsorbable stent is similar to that observed in Abbott's studies of metallic drug-eluting stents, with everolimus actively inhibiting tissue growth into the artery. The rate of device success (successful placement of the bioabsorbable stent at the site of the lesion) was 93.5 percent.


'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/9/2008)... Awareness and Bring Hope to Millions,of Children ...e/ -- 133 million children,across the globe are wi...disaster, civil war, and disease. SOS Children,s V...ek by calling attention to the needs of orphans,wo... to:, http://www.prnewswire.com/mnr/soschildrens...
(Date:10/9/2008)...s and Marketing Efforts to Accelerate ... PARK, Calif., Oct. 9 /- Evalve, Inc.... percutaneous repair of cardiac valves,has expand... appointment of,Sean Cleary as senior vice preside...ardson, as vice president of sales., "The additio...
(Date:10/9/2008)...titute, Navigenics, Affymetrix and,Microsoft team ... /- A consortium of health care,tech...a first-of-its-kind,research study to assess the b...ople who choose to receive such screenings to iden...iseases., Sponsored by Scripps Translational Scie...
(Date:10/8/2008)...re-USNewswire/ -- The facts are,overwhelming. Ever...b-Saharan Africa. More than 35,000,000 women, chil...ied of AIDS. The Foundation for Hospices,in Sub-Sa...eir families,find compassion and relief from suffe...ring initiative links African hospices and palliat...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 1Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 2Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 3Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 5Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 6Overuse of Opioids Barbiturates Boosts Chronic Migraine Risk 17140 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 2Migraines Frequency Influences Heart Attack Stroke Risk 17138 3Parents stricter with older kids to set example 3A game theory study 17136 1Parents stricter with older kids to set example 3A game theory study 17136 2
...h 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corp...l to,act as a potent payload in antibody conjugate...ion of the Handbook of Therapeutic,Antibodies. , I... Susanna,Rybak, Ph.D. summarizes preclinical resea... ONCONASE improves in a number of tumor,models, in...
...Enzyme Levels in Two Most Common Mutations, CRANBU...erapeutics, a biopharmaceutical company developing...al chaperones for the,treatment of a range of huma...resent the results of preclinical studies of,Plice...disease at,the of Medical Genetics (ACMG) annual m...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...reatment could help prevent future blood clots in ...mboembolism (VTE) affects approximately 2 million ...osis (blood clots common in the thigh and back) an...on in the lung). Despite progress in diagnosis and...
...ion for some patients with large liver tumors. The... //before using lasers to heat and destroy the tum...proves the overall survival of the patients. Radio...nduced thermotherapy (LITT) to heat tumors. The pr...
...on that can be fatal. It is defined as an obstruct... a blood clot, //which blocks a coronary artery. W...onary embolism, a new study shows a new treatment ...inister to patients than the current treatment. Ac...
...f the American Society of Therapeutic Radiology an...beam radiation may be what it takes to relieve pai...d to the bone. More than 160 hospitals and univers...were involved in a study of about 900 men and wome...
Other Medicine News:Health News:Extended Therapy for Blood Clots 2Health News:New Liver Tumor Treatment 2
...w XCD-SX910CR digital camera incorporates a Progre...excellent sensitivity (1280 (H) x 960 (V) SXGA. Wh...ask (commonly called a "Bayer filter") and outputs... converted to a color image on the computer. The c...
...661 is a monochrome " 1.3 Megapixel FireWire camer...s. Desgined to simplify real-time uncompressed vi...A661 provides uncompromising video and digital sti...-A661 is ideal for industrial inspection tasks inv...
...h acclaimed GT-CAPTURE digital camera photomicrogr...ers microscope such as Olympus, Leica, Nikon, and ...sferring images over the Internet easy and fast. F...ormance-proven Nikkor lens. The system records pho...
...0 is a superb stand-alone digital camera with netw...es from local or remote locations. Image acquisiti...amera operates independently or attaches directly ...o capture and transfer images. Sharing images in r...
Medicine Products: